Literature DB >> 9415737

Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996.

R M Kolhapure1, R P Deolankar, C D Tupe, C G Raut, A Basu, B M Dama, S D Pawar, M V Joshi, V S Padbidri, M K Goverdhan, K Banerjee.   

Abstract

During 1992-96, outbreaks of buffalopox zoonosis were reported from different villages in Jalgaon, Dhule and Beed districts of Maharashtra State. In humans, pox lesions were observed on the hands whereas in affected buffaloes and cows the lesions were noticed mainly on the teats and udder. Twenty two virus strains were isolated from the skin scabs collected from infected humans and milch animals. Neutralizing antibodies were detected not only in the sera of affected humans but also in their contacts. Detection of antibodies in young individuals from endemic area, who were neither vaccinated for smallpox nor had any contact with buffaloes or history of any poxvirus disease, is suggestive of occurrence of subclinical infection. A few children who had no contact with infected animals also showed clinical manifestations with disseminated lesions on the face, arm and buttocks, and thus suspected to have acquired infection through their infected parents or other family members indicating a possible man to man transmission. Therefore, in the light of discontinuation of smallpox vaccination, buffalopox outbreaks need to be monitored carefully as this may emerge as a serious zoonotic disease in India.

Entities:  

Mesh:

Year:  1997        PMID: 9415737

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  18 in total

1.  Genome of horsepox virus.

Authors:  E R Tulman; G Delhon; C L Afonso; Z Lu; L Zsak; N T Sandybaev; U Z Kerembekova; V L Zaitsev; G F Kutish; D L Rock
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  The poxvirus A35 protein is an immunoregulator.

Authors:  Kristina E Rehm; Gwendolyn J B Jones; Alice A Tripp; Mark W Metcalf; Rachel L Roper
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.

Authors:  Scott Parker; R Mark Buller
Journal:  Future Virol       Date:  2013-02-01       Impact factor: 1.831

4.  Primary Human B Cells at Different Differentiation and Maturation Stages Exhibit Distinct Susceptibilities to Vaccinia Virus Binding and Infection.

Authors:  Nicole Shepherd; Jie Lan; Wei Li; Sushmita Rane; Qigui Yu
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

5.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

6.  Partial antigenic characterization of buffalopox virus.

Authors:  P Anand Kumar; G Butchaiah
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

7.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Mark D Mannie; Rachel L Roper
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

9.  Nosocomial buffalopoxvirus infection, Karachi, Pakistan.

Authors:  Afia Zafar; Robert Swanepoel; Roger Hewson; Mazhar Nizam; Altaf Ahmed; Akhtar Husain; Antoinette Grobbelaar; Kevin Bewley; Valerie Mioulet; Barry Dowsett; Linda Easterbrook; Rumina Hasan
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

10.  Brazilian vaccinia viruses and their origins.

Authors:  Giliane S Trindade; Ginny L Emerson; Darin S Carroll; Erna G Kroon; Inger K Damon
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.